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ABSTRACT  
 
Tuberculosis (TB) causes significant morbidity and mortality on a global scale. The African region 
has 24% of the world TB cases. TB overlaps with other infectious diseases such as malaria and HIV 
which are also highly prevalent in the African region.  TB is a leading cause of death among HIV-
positive patients and co-infection with HIV and TB has been described as a syndemic. In view of 
the overlapping epidemiology of these diseases, it is important to understand the dynamics of 
the immune response to TB in the context of co-infection. We investigated the cytokine response 
to purified protein derivative (PPD) in peripheral blood mononuclear cells from TB patients co-
infected with HIV or malaria and compared it to that of malaria- and HIV-free TB patients. A total 
of 231 subjects were recruited for this study and classified into 6 groups; Untreated TB positive, 
TB positive subjects on TB drugs, TB and HIV positive, TB and malaria positive, latent TB, and 
apparently healthy control subjects.  Our results demonstrate maintenance of IFN-γ production in 
HIV and malaria co-infected TB patients in spite of lower CD4 counts in the HIV-infected cohort. 
Malaria co-infection caused an increase in the production of the Th2-associated cytokine IL-4 and 
the anti-inflammatory cytokine IL-10 in PPD-stimulated cultures. These results suggest that 
malaria co-infection diverts immunity response against M. tuberculosis towards a Th-2/anti-
inflammatory response which might have important consequences for disease progression.  
 
 
 
 
 
 
Keywords: tuberculosis, HIV, malaria, co-infection, cytokines 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 32 of 52Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
3 
 
Introduction 
 
Tuberculosis (TB) is an infectious disease that causes significant morbidity and mortality on a 
global scale [1]. Pulmonary tuberculosis caused by infection with Mycobacterium tuberculosis is 
the leading cause of death due to a bacterial pathogen and is responsible for 1.4 million deaths 
annually [2]. In 2011, there were an estimated 8.7 million new cases of TB and 1.4 million people 
died from TB, including almost one million deaths among HIV–negative individuals and 430,000 
among people who were HIV positive [3]. TB is second only to HIV/AIDS as the biggest killer 
worldwide due to a single infectious agent [4]. 
Host immune responses to infection are primarily characterized by a cell mediated response 
dominated by T-helper (Th) 1 cells playing a critical role in the secretion of IFN-γ; IFN-γ directs the 
effector response against mycobacteria through activation of macrophages, allowing them to 
exert a microbicidal role [5]. The crucial role of IFN-γ in immunity to mycobacteria has been 
demonstrated in studies of individuals with deficiencies in IFN-γ signalling due to mutations 
within the ifngr gene resulting in increased disease severity, poor granuloma formation and 
multibacillary lesions [6, 7].TNF-α also plays an important role in the latent phase of infection as 
TNF-α blockade in clinical and experimental models results in reactivation of latent tuberculosis 
[8]. 
Geographically, the burden of TB disease is highest in Asia and Africa. The African region accounts 
for 24% of the world’s cases and the highest rates of cases and deaths per capita [4]. TB is fuelled 
by HIV as well as by social and economic factors [9].Co-infection with HIV and tuberculosis has 
been described as a syndemic [10, 11].In Africa, HIV is the single most important factor 
contributing to the increase in the incidence of TB [12].TB is a leading cause of death among 
people who are HIV-positive; a quarter of all deaths in HIV-infected patients are caused by TB 
[10].Malaria is endemic in 109 countries and continues to cause between 189 and 327 million 
clinical episodes each year, with at least 881,000 associated deaths [13].TB overlaps with malaria 
which is prevalent in the African region [14].Malaria is endemic in Nigeria, particularly the P. 
falciparum species [15, 16]. HIV/AIDS, tuberculosis, malaria and neglected tropical diseases cause 
32% of the burden of ill health in Africa, and seriously impact on health outcomes in every region 
of the world [3].  
In view of the overlapping epidemiology of these diseases, it is important to understand the 
dynamics of the immune response to TB in the context of co-infection. Towards this aim we 
investigated the cytokine response to TB antigens in peripheral blood mononuclear cells (PMBCs) 
from TB patients co-infected with HIV or malaria and compared it to that of malaria- and HIV-free 
TB patients. Our results demonstrate maintenance of IFN-γ production in HIV and malaria co-
infected TB patients in spite of lower CD4 counts in the HIV-infected cohort. In contrast, changes 
were observed in IL-4 and IL-10 production among TB-infected groups. In particular, malaria co-
infection resulted in increased IL-4 and IL-10 secretion compared to malaria-HIV-free and HIV-co-
infected TB patients. Moreover, on the basis of TB-specific cytokine secretion, we were able to 
cluster our patient cohorts into groupings that align with their pathogen/treatment grouping 
which highlights the clinical relevance of our findings. These results suggest that malaria co-
infection promotes an anti-inflammatory response against M. tuberculosis which might have 
important consequences for disease progression. 
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Materials and Methods 
 
Ethics Statement 
Ethical approval for the study design was obtained from the Nnamdi Azikiwe University Teaching 
Hospital ethical committee (ethical approval reference number NAUTH/CS/66/3/21). Written 
informed consent was obtained from all participants enrolled in the study. 
 
Study populations 
Two hundred and thirty-one (231) subjects comprising one hundred and thirty-five (135) males 
and ninety-six (96) females with a mean age of 37 years, median age of 36 years (range 12-68 
years) were enrolled in the study at the Nnamdi Azikiwe University Teaching Hospital, Nnewi 
(Anambra State) and the Mile 4 hospital, Abakaliki (Ebonyi State). The subjects were classified 
into six groups according to their TB, anti-TB treatment, HIV and malaria parasitemia status: 
Group A: Untreated TB positive (n = 41); these subjects are TB positive only (HIV and malaria 
negative) but had not commenced anti-TB drugs, Group B: TB positive on drugs (n = 65); TB 
positive only and have commenced on anti-TB drugs, Group C: TB and HIV positive (n = 37); newly 
diagnosed to be TB and HIV positive but malaria-negative subjects who had not commenced anti-
TB drugs or anti-retroviral therapy, Group D: TB and malaria positive (n = 23); TB positive subjects 
co-infected with malaria but had not commenced on  anti-TB therapy or anti-malaria drugs, 
Group E: latent TB positive subjects (n = 30); apparently healthy subjects who were found to be 
latently infected with TB after mantoux screening, and Group F: healthy control subjects (n = 35), 
these had no reaction after mantoux testing. The TB disease group were enrolled after clinical 
assessment and were referred for laboratory testing using Ziehl-Neelsen and Auramine-phenol 
fluorochrome technique for Acid fast bacilli (AFB), and by Polymerase chain reaction (PCR) using 
the GeneXpert MTB/RIF assay (Cepheid, California). After samples had been collected from 
apparently healthy controls, subjects were administered with 0.1ml/5TU purified protein 
derivative (mantoux testing) to classify them into latently TB infected and control groups. As a 
precaution, children less than 12 years and adults who had received BCG vaccine in adulthood 
were excluded to rule out false positives. All the TB patients were classified according to chest X-
ray, PCR and sputum smear bacterial density into mild, moderate and severe TB. For uniformity, 
equal numbers of each category was targeted for each of the four (4) TB disease groups. No 
significant evidence of increased lung compromise was observed in any TB disease group 
compared to the other groups. In the TB positive group on drugs, no matter the drug duration, 
the recruited patients were sputum smear positive, had persistent clinical features of disease, 
abnormal chest X-ray findings and a positive PCR test. Some patients in this category had multi-
drug resistant TB. Based on BCG scars and questionnaires, not all subjects were BCG vaccinated. 
Approximately 60% from each group was vaccinated. A large number of individuals below 30 
years had BCG scars as they were vaccinated as part of routine childhood vaccination.  
Subjects were tested for HIV infection using Determine (Inverness Medical, Japan) and STAT-Pak 
(Chembio, USA) and in the event of discordant results, Uni-Gold (Trinity Biotech, Ireland) was 
used as the tie breaker according to the national guidelines for HIV counselling and testing [43]. 
Malaria testing was performed using thin and thick films as well as by using rapid MP test kits (SD 
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Bioline, Standard Diagnostics Inc, Korea). Patients and other subjects were excluded if they were 
pregnant, had any other clinical problems or had commenced anti-retroviral therapy.  
 
CD4 T cell and differential counts 
Blood samples were collected in EDTA vacutainer blood collection tubes (BD, USA) and CD4
+
 T cell 
counts were measured within 5 hours of sample collection, using a Cyflow SL.3 cytometer for 
automated CD4+ counts as per manufacturer’s instructions (Partec, Germany). For full differential 
white blood cell (WBC) counts, thin blood films were prepared, stained by Leishman’s technique 
and counted manually using x100 magnification following standard procedure. 
 
Isolation and stimulation of PBMCs 
Fresh EDTA anticoagulated blood was diluted 1:1 in Hanks’ balanced salt solution (HBSS, Sigma-
Aldrich). The mixture was then layered over Histopaque-1077 (Sigma-Aldrich) and centrifuged at 
800 x g for 30 minutes. PBMCs were collected and washed thrice in HBSS. Cells were re-
suspended in RPMI-1640 complete medium (all components from Sigma-Aldrich) containing 10% 
human AB serum, 2mM L-glutamine, 100U/ml penicillin, 100 µg/ml streptomycin and 10 mM 
HEPES. Cells were then cultured in sterile 96 well plates (Corning NY) in quadruplicate. Each well 
contained 200 μl of cell suspension (2x10
5 
cells/well) and PPD (2 μg/ml, BB-NCIP Ltd, Sofia, 
Bulgaria). Cultures were incubated for 72 hours at 37
o
C with 5% CO2 in a humidified incubator. 
Supernatants were collected; centrifuged at 800 x g for 15 minutes at room temperature and 
stored in aliquots at -20
o
C until cytokine measurement.  
 
Cytokine Assay 
The cytokine levels in supernatants of cultured PBMCs were measured using commercial ELISA 
kits (Abcam, Cambridge, UK) according to manufacturer’s instructions. Samples were assayed in 
duplicate for IFN-γ, TNF-α, IL-2, IL-4, and IL-10. The lower limit for assay sensitivity were <5 pg/ml 
for IFNγ, <10 pg/ml for TNF-α, <10 pg/ml for IL-2, <0.5 pg/ml for IL-4, <5 pg/ml for IL-10 as stated 
by the manufacturer. Cytokine release by unstimulated and PPD-stimulated cultures were 
assessed in two samples per patient group as controls. In all instances, unstimulated cultures 
produced less cytokines than PPD-stimulated cultures which indicates that the cells were 
responsive to stimulation under our assay conditions. 
 
 
Statistical analysis 
Data were analysed using Kruskall-Wallis test with Dunn’s multiple comparison correction (Graph 
pad prism version 5.03) and the level of significance set at P<0.05. For clustering analysis data 
were analyzed using SPSS (IBM Version 21). Briefly, samples were transformed to Z-scores to 
enable agglomerative hierarchical clustering. Z-scores were used due to the variable nature of 
the scale of cytokine production both within individual cytokine variables and across the cytokine 
variables. A pre-defined number of clusters were set at 12 to allow for potential variation, i.e. 
high cytokine responder or non-responder, within each of the six nominal groups of patients 
recruited to the study. Clustering was performed twice using two measures of distance to define 
the distance between clusters, complete and average linkage. The distance measures were first 
sorted to determine cytokine similarity and further sorted to allow alignment of patients.  
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Results 
 
Demographics and CD4+ T-cell counts of patient groups  
The demographics of the study population and each patient group are displayed in Table 1. The % 
of male subjects in the patient groups was higher than the % of female patients, ranging from 
56.7% to 60.9%. The median age ranged from 36±10.1 to 38.2±7.8 and patients in the lower 
socio-economic status were overrepresented in all TB subjects except the TB-malaria co-infected 
group.  
CD4
+
T-cell counts (cells/μl) (Figure 1)were significantly lower in all the active TB infected groups 
(untreated TB subjects [737 ± 266], TB positive subjects on TB drugs [807 ± 252], TB and HIV 
positive subjects [258 ± 203] and TB and MP positive subjects [611 ± 271], but not in the latent TB 
positive subjects (1046 ± 305) when compared with the control (1083 ± 281) group (P < 0.01). The 
total lymphocyte counts (x10
9
) were 1.81 ± 0.99 in the untreated TB positive subjects, 1.79 ± 0.67 
in TB positive subjects on drugs, 1.62 ± 0.94 in TB and HIV positive subjects, 2.28 ± 1.00 in TB and 
MP positive subjects, 2.13 ± 0.79 in Latent TB positive subjects and 2.07 ± 0.76 in apparently 
healthy controls. There were no significant differences between the test and control groups 
(P>0.05).Other WBC counts such as eosinophils, monocytes and basophils showed no divergence 
from the expected normal ranges (see supplementary Table 1). Monocyte/lymphocyte ratios 
were also calculated and no differences among groups were observed (data not shown). The lack 
of eosinophilia and basophilia would suggest no underlying helminth infection. Hypoalbuminemia 
is a non-specific indicator of helminth infection; serum albumin levels of all patients were 
examined. In agreement with the eosinophil data, no changes were found in the albumin levels 
among groups with respect to normal ranges of 35-50g/L (data not shown).   
 
Cytokine production by patients’ PBMC cultures 
PBMCs from subjects belonging to each patient group were stimulated with PPD for 72 hours as 
described in materials and methods and supernatants were collected and tested for the presence 
of the effectors cytokines TNF-α and IL-2 (Figure 2), the Th1/Th2 signature cytokines IFNγ and IL-4 
(Figure 3) and the regulatory cytokine IL-10 (Figure 4).   
The median values obtained for TNF-α (pg/ml) were 138 (range 1.9 – 574) for the untreated TB 
positive subjects, 130 (range 30 – 2,267) for the TB positive subjects on drugs, 139 (range 24 - 
421) for TB and HIV positive subjects, 213 (105 – 526) for TB and malaria positive subjects, 215 
(range 78 – 613) for the latent TB positive subjects and 0.0 (range 0 – 103) for the apparently 
healthy controls. TNF-α levels were significantly increased in all TB patients compared to controls 
with differences among the TB infected only reaching significance when comparing the latent TB 
group and active TB group on anti-TB drugs (p=0.0156).  
 
The median values obtained for IL-2 in pg/ml were 141.0 (range 36 – 503) for the untreated TB 
positive subjects, 116.0 (range 30 – 480) for the TB positive subjects on drugs, 115 (range 39 - 
215) for TB positive HIV positive subjects, 136 (66 – 315) for TB and malaria positive subjects, 156 
(range 86 – 321) for the Latent TB positive subjects, 175 (range 86 – 410) for the apparently 
healthy controls.IL-2, a surrogate marker of T cell activation, was readily detected in all cultures. 
The findings reveal that IL-2 levels were significantly lower in the TB positive group on drugs and 
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the HIV co-infected TB group when compared to the latent TB positive subjects and healthy 
control subjects.  However, there were no significant differences when comparing the MP co-
infected and the untreated TB group to the latent and control group (Fig 2). 
 
The median values for IFN-γ in pg/ml were 554.0 (154 – 1399) for the untreated TB positive 
subjects, 596.0 (170 -1710) for the TB positive subjects on drugs, 543.0 (136 – 1048) for the TB 
and HIV positive subjects, 536.0 (108 – 1360) for the TB and malaria positive subjects, 817.5 (360 
– 1430) for the Latent TB positive subjects and 215.0 (106 – 430) for the control subjects. IFN-γ, 
an indicator of Th1 polarisation was detected in all instances with significantly higher amounts 
being measured in the TB-infected groups compared to control group (Fig 3). As expected, the 
latent TB group produced significantly higher amounts of IFN-γ than the control subjects upon 
PPD stimulation.  Latent TB subjects produced significantly more IFN-γ than the TB-infected group 
on drugs (p = 0.0341), TB-HIV co-infected group (p = 0.0097) and the TB-malaria co-infected 
group (p = 0.0084).  No differences in IFN-γ production were observed among the active TB-
infected groups. 
  
IL-4, an indicator of Th2 polarisation was detected in low amounts in all instances as expected for 
PPD-stimulated cultures. The median value obtained for IL–4 in pg/ml were 7.6 (0.0 – 229.0) for 
untreated TB positive subjects, 5.7 (0.0 – 25.6) for TB positive subjects on drugs, 2.3 (0.0 – 47.0) 
for TB and HIV positive subjects, 33.0 (3.8 – 72.0) for TB and MP positive subjects, 1.6 (0.0 – 36.0) 
for the Latent TB positive subjects, 38.0 (0.0 – 182) for the apparently healthy controls. The 
control group produced significantly higher amounts of IL-4 compared to all TB-infected groups 
with the exception of the TB patients co-infected with malaria (Fig 3). It is interesting to note 
from our findings that the TB-malaria co-infected patient subset produced significantly higher 
levels of IL-4 than all other TB infected groups with production levels similar to that found in the 
control group. This level of production in TB-malaria indicates an increase in anti-inflammatory 
response to M. tuberculosis. 
 
Finally, IL-10 production differentiated patient groups into low producers (control and Latent TB), 
mid producers (treated TB, untreated TB and TB patients co-infected with HIV) and high 
producers (TB patients co-infected with malaria). The IL – 10 median values in pg/ml were 110.0 
(range 5.0 – 241.0) for untreated TB positive subjects, 114.0 (56 – 312) for TB positive subjects on 
drugs, 119.0 (49.0 – 216) for TB and HIV positive subjects, 221.0 (118.0 – 563.0) for TB and 
malaria positive subjects, 4.6 (0.0 – 49.0) for the Latent TB positive subjects, 8.0 (0.0 – 52) for the 
apparently healthy controls. Graph shows median and 5-95 percentiles. No differences between 
control and Latent TB were observed. Differences between control and Latent TB groups and all 
active TB groups were highly significant for IL-10 production. The TB-malaria co-infected group 
produced significantly higher levels of IL-10 compared to untreated TB patients (p = 0.0006), TB 
patients on drugs (p = 0.001) and TB-HIV co-infected patients (p = 0.0036). The high IL-10 
production in the TB-malaria co-infected group indicates the prevalence of more anti-
inflammatory conditions in this particular group of patients.  
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Cluster analysis of patient groups 
To determine if the cytokine responses we determined corresponded to valid patient 
clusters/groupings we undertook agglomerative hierarchical cluster analysis. The resulting 
dendrogram (Figure 5A) illustrates the resulting clusters. Clustering was undertaken twice using 
two differing definitions of distance – complete and linkage. On both occasions the resulting 
clusters indicated the same relationships – there are two major clusters one corresponding to 
control, latent TB and TB-HIV co-infected patients and the second corresponding to TB patients 
on drugs, TB patients not on drugs and TB-malaria co-infected patients. In cluster one latent TB 
and TB-HIV co-infected patients were more closely associated and in cluster two TB patients on 
drugs and TB patients not on drugs were most closely related. These relationships were then 
represented using a heatmap (Figure 5B). Cytokines production was calculated as % increase over 
the control group average for each individual within the remaining patient groups. Thereafter, 
patient group responses were averaged to produce the heatmap which demonstrates that the 
greatest gradients in responses across groups were seen in IL-10 and TNF-α. 
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Discussion 
 
The main findings of this study are the changes that were observed in the TB-malaria co-infected 
group which displayed increased IL-4 and IL-10 secretion compared to other TB-infected groups. 
In addition, the patient cohorts could be clustered into groupings that align with their 
pathogen/treatment characteristics which highlight the relevance of our results. 
The observations regarding socio-economic status in this study were in agreement with the link 
between TB infection and socioeconomic status previously described with prevalent TB 
significantly associated with poverty and lower household socio-economic positions [17, 18]. 
In this study, immunological markers in TB were investigated by assessing CD4+ counts and 
quantifying cytokine production by PPD-stimulated PBMCs in controls and TB-infected groups. 
CD4+ T cell counts (Figure 1) and total lymphocyte counts (see supplementary Table 1) in the 
Latent TB group were comparable to what was observed in the control group and higher than 
values observed in active TB samples showing that in these individuals CMI is optimal.  
TNF-α, IL-10 and IFN-γ were preferentially detected in TB-infected samples although substantial 
IFN-γ could also be detected in control samples. These results indicate that production of these 
cytokines was largely due to the presence of memory cells. IL-2 and IL-4 were detected in both 
control and TB-infected supernatants. IL-2 levels were significantly reduced in TB patients on 
drugs and TB-HIV co-infected samples compared to control and Latent TB. Levels of IL-4 were low 
in general and controls and TB-malaria co-infected samples contained significantly more IL-4 than 
the rest of the groups, particularly when compared to the Latent TB group that produced the 
lowest amounts of IL-4.  
 
Differences between Latent TB vs. active TB groups 
In general PPD-induced responses in Latent TB was characterized by similar production of TNF-α, 
IL-2, IFN-γ and lowest production of IL-4 and IL-10 suggesting a robust Th1-dominated response in 
line with the fact that TB is controlled in these patients. These results agree with that of Handzel 
et al (2007) [19] who reported that PPD-stimulated cells of latently infected subjects secreted 
more IFN-γ and IL-2 and may contribute to protection from overt disease. Functional capacity to 
produce certain cytokines is associated with mycobacterial load [20]. Day et al (2011) [20] 
reported that patients with latent TB infection produced higher levels of cytokines than those 
with clinical TB. They suggested that there is progressive impairment of mycobacterium-specific T 
cell responses with increasing mycobacterial load. However, in contrast to our findings some 
researchers [21] reported higher IFN-γ level in active TB cases compared to latently infected 
individuals. 
IL-2, IFN-γ and other Th1 cytokines play a role in the control of intracellular infections while type 
2 cytokines (IL-4, IL-5, IL-10) are either irrelevant or exert a negative influence [22]. IFN-γ is a key 
cytokine in control of TB infection [23, 24, 25]. TNF-α induces inflammatory responses and is 
critical to host resistance to TB [26, 27, 28]. IL-4 is the most powerful trigger for Th2 development 
and is antagonistic to Th1 cytokines [29]. Diminished production of IL-4 has been reported in TB 
infected individuals compared with healthy controls [30]. IL-10 has emerged as a key 
immunoregulator during infection that can inhibit both Th1 and Th2 responses [31]. It has been 
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reported that experimental ablation of IL-10 or inhibition of IL-10 signalling restores pathogen 
control and reduces the severity of disease [31].  
 
Co-infection with HIV and malaria modulate anti-TB responses  
Human populations are rarely exposed to one pathogen alone, particularly in high incidence 
regions [32]. In comparison to mono-infection, co-infection presents a more complex challenge to 
the host immune system [33].It has been reported that  TB co-infection with parasitic infections 
in animals present enhanced inflammatory immune responses as reflected by exacerbated 
leukocyte infiltrates, tissue pathology and hypercytokinemia accompanied by altered T cell 
responses [32].It is estimated that 14 million people are co-infected with HIV and TB, with 
tuberculosis being the most common opportunistic infection in HIV and accounting for over a 
quarter of AIDS related deaths [34].Given the complexity of the immune response, there are 
multiple ways that HIV can alter the immune response to M .tuberculosis [35] including CD4+ T 
cell depletion. CD4+ T cell depletion was associated with decline in memory (CD 27
+
CD45RO
+
) 
CD4+ T cells that recognize M. tuberculosis antigens [36].Multivariate analysis placed TB-HIV co-
infected samples closest to controls and Latent TB samples indicating a distinct effect of HIV 
infection on TB-specific cytokine responses during active TB. The effect of HIV infection does not 
appear to be caused by general immunosuppression. Immune cells from TB-HIV co-infected 
patients produced levels of cytokines similar to those observed in other patient groups in spite of 
the significantly lower numbers of CD4+ T cells detected in these donors at the time of sampling.  
For IL-4 TB-HIV co-infected patients tended to align with the Latent TB group (lowest IL-4 
production), while for IL-10 the TB-HIV co-infected donors produced levels similar to those 
produced by the untreated and treated TB groups (intermediate IL-10 production). In the case of 
TNF-α, this cohort could not be differentiated from the Latent TB and other TB-infected cohorts.  
For IL-2 and IFN-γ this group could be differentiated from controls and Latent TB but no other TB-
infected groups. These observations suggest a Th1 bias with increased regulatory potential 
(intermediate IL-10) in these TB-HIV patients compared to the TB only groups (both treated and 
untreated).This would be in agreement with the suppression of cellular immune responses by 
regulatory T cells induced by HIV infection in TB previously described[37]. 
In this study, among the individuals who were co-infected with malaria parasite and TB, none had 
severe anaemia, acute respiratory distress syndrome, neurological disorders and other 
manifestations characteristic of severe malaria. None of the patients complained of malaria 
symptoms during questioning in spite of the parasite counts (median 29,520 parasites/µl, 5% 
17,595 parasites/µl and 95% 67,520 parasites/µl) which, although modest should cause 
symptomatic malaria. There could be reasons for this. First, clinically, malaria infection causes a 
range of symptoms from asymptomatic or mild flu-like illness (uncomplicated malaria), 
particularly in individuals immune to malaria in endemic areas, to the uncommon complications 
of severe disease [38].The study area is a malaria endemic region where Plasmodium falciparum 
causes most malarial disease. Adults with some level of immunity to malaria may be infected 
with malaria, have few clinical symptoms and rarely experience severe complications (with the 
exception of pregnant women) [39]. Additionally, co-infection with TB could mask the malaria 
symptoms since the symptoms of both diseases overlap. Moreover, it has been reported that TB-
induced potentiation of type 1 immune responses is associated with protection against lethal 
murine malaria and this protective process is believed to relate to IFN-γ induction [40]. Riley et al 
[41] reported that this induction of cellular immune responses is related to the ATP-binding 
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protein (ATPBP) of plasmodium species. Also according to Zheng et al [42], heat shock protein 70 
(HSP 70) from M.tuberculosis was associated with the induction of a strong humoral and cellular 
response directed against Plasmodium falciparum which further support an interplay between TB 
and malaria immune responses. 
For TNF-α, IL-2 and IFN-γ production the TB-malaria co-infected cohort could not be 
differentiated from the other TB-infected cohorts. This pro-inflammatory response could be 
protective against severe malaria.  
It is interesting to note that the TB-malaria co-infected group produced highest levels of IL-4 and 
IL-10, which are unique characteristics of this group. This observation was validated by the 
multivariate analysis. These observations indicate there is reduced Th1 bias and increased 
regulatory potential in the TB-malaria co-infected group and support a major effect of malaria 
infection in anti-TB immunity. No differences were observed in between TB patients undergoing 
chemotherapy and those untreated. Since there were significant differences in all the TB infected 
groups (with the exception of the TB-malaria co-infected group) compared to the control group, 
this then indicates that M. tuberculosis suppresses the production of IL-4. On the other hand, 
there was no significant difference in IL-4 production between the control group and the TB-
malaria co-infected subset. This suggests that co-infection with malaria increases production of 
IL-4 and favours an anti-inflammatory response to M. tuberculosis. It can be argued that perhaps 
the TB-malaria co-infected group have more severe disease and this could be responsible for 
increased production of IL-4. This is however not the case as this group had no evidence of 
increased lung compromise when compared to other TB infected groups. The control group 
produced relatively high levels of IL-4 and helminth infection could be suspected. Though stool 
analysis was not performed to assess for helminth infection, the low eosinophil numbers in all 
samples (Supplementary Table 1) indicate that helminth infection would be unlikely not just in 
the control group but in all groups studied. Thus, the probability of helminth infection would be 
the same for all study groups. 
 
In conclusion, findings from this study suggests that the higher pro-inflammatory cytokines seen 
in Latent TB is an evidence of protection while higher anti-inflammatory and regulatory cytokines 
in other TB test subjects may indicate failure of protection. Thus, a balance of these two types of 
cytokines (inflammatory and anti-inflammatory) groups may be critical to non-progression to TB 
disease. Our results demonstrate maintenance of IFN-γ production in HIV and malaria co-infected 
TB patients in spite of lower CD4 counts. This study also suggests that co-infection with TB may 
modulate the immune responses to confer immunologic protection against severe malaria while 
weakening responses to TB. Malaria co-infection caused a marked increase in the production of 
the anti-inflammatory cytokines IL-10 and IL-4 in response to TB antigen. These results suggest 
that malaria co-infection promotes an anti-inflammatory response against M. tuberculosis which 
might have important consequences for disease progression. In view of these findings, future 
work will focus on comparison of TB disease progression in TB versus TB and malaria co-infected 
patients.  
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Table 1: Demographic characteristics of the groups of patients investigated, latent group and 
controls 
Characteristics        Group  A             Group B         Group C        Group D           Group E      Group F 
                                   (n=41)                  (n=65)             (n=37)          (n=23)               (n=30)         (n=35)   
 
Age range                12-68                    16-63             24-56            22-68                 18-56                16-64 
(years) 
Mean Age               36.5 + 13.5         37.5 + 11.4     38.2+ 7.8     36.0 + 10.1       36.3 + 10.6         37.3 
+ 11.6 
( +SD) 
Sex 
Males                       24(58.5%)          38(58.5%)         21(56.8%)   14(60.9%)       18(60.0%)          
20(57.1%)                               
Females                   17(41.5%)          27(41.5%)         16(43.2%)    9 (39.1%)        12(40.0%)         
15(42.9%) 
Socio-economic 
Status 
Low                           30(73.2%)          42(64.6%)         22(59.5%)     15(65.2%)       16(53.3%)        
15(42.9%) 
Medium-High          11(26.8%)         23(35.4%)          15(40.5%)      8 (34.8%)       14(46.7%)        
20(57.1%) 
 
Key = Untreated TB positive subjects (A), TB positive subjects on drugs (B), TB and HIV positive 
subjects (C), TB and malaria positive subjects (D) Latent TB subjects (E), Apparently healthy 
control group (F) 
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Figure legends 
 
Figure 1. 
CD4+ T-cell counts from patient groups.  
Patients were grouped according to disease diagnosis plus or minus TB chemotherapy into the 
following groups; controls (Cont), Latent TB (Lat-TB), active TB without chemotherapy (TB+Drug-) 
or with chemotherapy (TB+Drug+), TB-HIV co-infection (TB+HIV+) and TB-malaria (TB+MP+) co-
infection. CD4 counts were determined using blood collected in EDTA analyzed with an 
automated Cyflow SL.3 cell cytometer. Counts are expressed as cells/μl. Graph shows median and 
5-95 percentiles. Statistical significance between groups was determined using a Kruskal-Wallis 
test with Dunn’s multiple comparison correction; *p<0.05, **p<0.01, ***P<0.001, ****p<0.0001. 
Significant differences among Controls and Latent-TB and active TB groups are shown in grey. 
Significant differences among active TB groups are shown in black.  
 
 
Figure 2. 
Production of TNF-α and IL-2 by TB patient groups. 
Patients were grouped according to disease diagnosis plus or minus TB chemotherapy into the 
following groups; controls (Cont), Latent TB (Lat-TB), active TB without chemotherapy (TB+Drug-) 
or with chemotherapy (TB+Drug+), TB-HIV co-infection (TB+HIV+) and TB-malaria co-infection 
(TB+MP+).Concentrations of TNF-α and IL-2 in supernatants were quantified using ELISA as 
described in materials and methods. Graph shows median and 5-95 percentiles. Statistical 
significance between groups was determined using a Kruskal-Wallis test with Dunn’s multiple 
comparison correction; *p<0.05, **p<0.01, ***P<0.001, ****p<0.0001. Significant differences 
among Controls and Latent-TB and active TB groups are shown in grey. Significant differences 
among active TB groups are shown in black.  
 
 
Figure 3. 
Production of IFN-γ and IL-4 by TB patient groups. 
Patients were grouped according to disease diagnosis plus or minus TB chemotherapy into the 
following groups; controls (Cont), Latent TB (Lat-TB), active TB without chemotherapy (TB+Drug-) 
or with chemotherapy (TB+Drug+), TB-HIV co-infection (TB+HIV+) and TB-malaria co-infection 
(TB+MP+).Concentrations of IFN-γ and IL-4 in supernatants were quantified using ELISA as 
described in materials and methods. Graph shows median and 5-95 percentiles. Statistical 
significance between groups was determined using a Kruskal-Wallis test with Dunn’s multiple 
comparison correction; *p<0.05, **p<0.01, ***P<0.001, ****p<0.0001.Significant differences 
among Controls and Latent-TB and active TB groups are shown in grey. Significant differences 
among active TB groups are shown in black.  
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Figure 4. 
Production of IL-10 by TB patient groups. 
Patients were grouped according to disease diagnosis plus or minus TB chemotherapy into the 
following groups; controls (Cont), Latent TB (Lat-TB), active TB without chemotherapy (TB+Drug-) 
or with chemotherapy (TB+Drug+), TB- HIV co-infection (TB+HIV+) and TB-malaria co-infection 
(TB+MP+).Concentrations of IL-10 in supernatants were quantified using ELISA as described in 
materials and methods. Statistical significance between groups was determined using a Kruskal-
Wallis test with Dunn’s multiple comparison correction; *p<0.05, **p<0.01, ***P<0.001, 
****p<0.0001. Significant differences among Controls and Latent-TB and active TB groups are 
shown in grey. Significant differences among active TB groups are shown in black.  
 
 
Figure 5. 
Cluster analysis of patient cytokine production.   
Patients were grouped according to disease diagnosis plus or minus TB chemotherapy into the 
following groups; controls (Cont), Latent TB (Lat-TB), active TB with chemotherapy (TB+drug+) or 
without chemotherapy (TB+drug-), TB-HIV co-infection (TB+HIV+) and TB-malaria co-infection 
(TB+MP+).(A)Cluster analysis was undertaken using SPSS (Version 21 – IBM). Cytokine values 
were transformed to Z-scores prior to undertaking clustering. Two distance measures were used, 
complete and linkage distance. A finite number of clusters, 12, were pre-determined.(B) A 
heatmap was generated corresponding to each cluster for average cytokine production. Control 
values were averaged and individual values from remaining patient groups were calculated as a % 
change over control values.  
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Mean (+ SD) of CD4 + T cell counts, WBC and differential counts in tuberculosis infected subjects and the apparently healthy control subjects. 
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 Groups CD4(cells/µl) TWBC(109/l) ABSOLUTE 
LYMPH 
(x10
9
) 
ABSOLUTE 
NEUT(x10
9
) 
LYMPH (%) NEUT (%) MONO (%) EOSIN (%) BASO (%) 
Untreated TB pos. subjects 
(n=41)(A) 
737+266
* 
3.95+2.36 
 
1.81+.99 2.05+.15 46.8+11.1
* 
49.9+11.5
* 
 
2.2+0.9 0.8+1.0 0.3+0.7 
TB positive subjects on drugs 
(n=65) (B) 
 
807 +252
*
 3.79+1.51 1.79+.67 1.88+.99 48.3+10.0
* 
48.9+10.0
*
 2.1+0.9 0.8+0.8 0.5+0.8 
TB and HIV positive subjects 
(n=37) (C) 
 
258+203
*
 3.98+2.15 1.62+.94 2.27+.15 41.2+10.9
* 
55.9+11.3
*
 2.00+0.9 0.7+0.8 0.4+0.7 
TB and MP positive subjects 
(n=23) (D) 
 
611+271
*
 4.57+2.42 2.28+ 1.0 2.20+1.80 53.3+17.3 44.0+17.6 2.5+0.8 0.7+0.9 0.08+0.2 
Latent TB positive subjects 
(n=30) (E) 
 
1046+305 4.17+1.67 2.13+.79 1.9+1.09 52.1+10.5 45.2+10.4 1.9+0.9 0.8+1.1 0.73+0.8 
Apparently healthy controls 
(n=35) (F) 
 
1083+281 3.82+1.23 2.07+.76 1.6+.65 54.9+10.0 41.3+9.6 2.4+0.9 1.00+0.8 0.43+0.6 
F Value 46.86 0.69 
 
2.78 1.43 6.83 7.18 1.87 0.43 2.22 
P Value 
 
0.00
*
 0.63(ns) 0.01
*
 0.21(ns) 0.00
*
 0.00
*
 0.10(ns) 0.31(ns) 0.05(ns) 
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